Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients

The 1-year THALASSA study enrolled 166 patients with various non-transfusion-dependent thalassemia (NTDT) syndromes, degrees of iron burden and patient characteristics, and demonstrated the overall efficacy and safety of deferasirox in reducing liver iron concentration (LIC) in these patients. Here,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Taher, Ali T, Porter, John B, Viprakasit, Vip, Kattamis, Antonis, Chuncharunee, Suporn, Sutcharitchan, Pranee, Siritanaratkul, Noppadol, Galanello, Renzo, Karakas, Zeynep, Lawniczek, Tomasz, Habr, Dany, Ros, Jacqueline, Zhang, Yiyun, Cappellini, M Domenica
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2013
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3698696/
https://ncbi.nlm.nih.gov/pubmed/23553596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23445
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars